new business management intelligent job ideas financial investment money markets need loan a guide in your house getting more money health sector getting loan making sturdy roof online income tips security home show yourself more beautiful investment in jewellery famous special life tourism places you need to go start new job how to choose your vehicle creating new products to earn women makeup tools how to loss your fat vehicle insurance choosing tips how train your muscles choose best decoration for you house how many insurance tips exist whats is new in tech protect your health new dresses your company book suitable insurance life in house which business best for me individual loan form meal ingredients how to choose correct companies which job? how to choose best product tech and life how to make home business guide in your business income and outcome types of different businesses how to choose suitable insurance income from cars money & markets heatlhy fat loss how to decore your home protect your money via security
Biomaterials and Advanced Drug Delivery

Biomaterials and Advanced Drug Delivery Laboratory

Cardiovascular Pharmacology Division of CVI


For an enhanced experience, get the free flash player


Biomaterials and Advanced Drug Delivery Laboratory

The Biomaterials and Advanced Drug Delivery (BioADD) Laboratory is a cutting edge research facility founded in 2010 on the Stanford University Medical Campus. Today’s problems in drug design require complex answers to achieve effective delivery and treatment. The Stanford BioADD Lab helps to solve these problems with advanced modern technology and innovative solutions. Specializing in the creation of biomaterials and drug delivery agents, the lab lends its expertise toward designing and analyzing biomaterials, developing drug delivery devices and formulations, pharmacokinetic and pharmacodynamic studies, and developing smart materials for biomedical applications.



Methylene Blue

Why are Alzheimer's drug developers getting the blues? It depends on what's meant by "getting the blues."

The field has been plagued by a succession of failures of one experimental drug after another, Stanford drug researcher Jay Rajadas, PhD, tells me, with promising effects shown in early clinical trials disappearing like mist in the morning in crucial large-scale late trials. In response, big pharmaceutical companies have gradually abandoned their onetime obsession with ridding Alzheimer’s patients’ brains of gummy extracellular deposits known as amyloid plaques. . .


Footer Links: